Viatris

Yahoo Finance • 3 days ago

Most healthcare companies report higher Y/Y EPS in strong earnings week

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare companies delivered strong earnings this week, with 18 out of 20 companies beating EPS estimates and 15 t... Full story

Yahoo Finance • 5 days ago

Chris Davis Significantly Reduces Stake in Applied Materials Inc, Impacting Portfolio by -3.47%

This article first appeared on GuruFocus. Insight into Chris Davis (Trades, Portfolio)'s Strategic Moves in Q1 2026 Warning! GuruFocus has detected 4 Warning Sign with AIG. Is COF fairly valued? Test your thesis with our free DCF calcula... Full story

Yahoo Finance • 5 days ago

Cardiogenic Shock Analysis Report 2026: Market to Reach $5.2 Billion by 2030, Driven by Minimally Invasive Techniques, AI Adoption. and Aging Populations

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Cardiogenic Shock Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global cardiogenic shock market value in 2024 stood at US$3.57 billion, and is projected to... Full story

Yahoo Finance • 10 days ago

Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

[Magnifying Glass On Top Of Bar Chart] DNY59 Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue i... Full story

Yahoo Finance • 11 days ago

Chlorpheniramine Maleate - Global Market Insights, Competitive Landscape & Industry Forecast to 2033 Featuring Viatris, Alkem Labs, Merck & Co., Johnson & Johnson, Capellon Pharma and More

Company Logo The chlorpheniramine maleate market is poised for growth due to rising allergic conditions, OTC antihistamine awareness, and pharmaceutical innovation Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Chlorpheniramine Maleate Ma... Full story

Yahoo Finance • 26 days ago

QSM Asset Management Loads Up 611,000 Mobileye Shares

Key Points QSM Asset Management Ltd bought 611,003 shares of Mobileye, with an estimated trade value of $5.54 million based on quarterly average pricing. The quarter-end value of the new Mobileye stake was $4.13 million. This trade repres... Full story

Yahoo Finance • 28 days ago

Quant check on David Einhorn's Greenlight Capital holdings post Q1

[Close up image of wooden cubes with alphabet Q1 on office desk.] mohd izzuan David Einhorn's Greenlight Capital funds gave a return of 6.5% in Q1 vs. a broader market drop of 4.4% in the S&P 500 index. The significant winners in the quar... Full story

Yahoo Finance • last month

Australia Drug Delivery Devices Market Trends by Type of Product, Application Area and End-user - Forecast to 2035

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Australia Drug Delivery Devices Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Application Area and End-user" has been added to ResearchAndMarke... Full story

Yahoo Finance • last month

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 2 months ago

Viatris Outlines Long-term Financial Targets

(RTTNews) - Viatris (VTRS) said, for combined long-term Targets through 2030, the company expects to deliver 5% to 6% total revenues CAGR, 7% to 8% adjusted EBITDA CAGR, 9% to 10% adjusted EPS CAGR and more than $3 billion in annual free c... Full story

Yahoo Finance • 2 months ago

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Not all companies are created equal, a... Full story

Yahoo Finance • 2 months ago

ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?

The Vanguard Small-Cap Value ETF (NYSEMKT:VBR) and iShares Morningstar Small-Cap Value ETF(NYSEMKT:ISCV) both target U.S. small-cap value stocks, but ISCV offers a marginally higher yield, heavier exposure to financial services, and much s... Full story

Yahoo Finance • 2 months ago

What Are Analysts Saying About Viatris Inc (VTRS) Stock?

Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 2... Full story

Yahoo Finance • 2 months ago

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story

Yahoo Finance • 2 months ago

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline

On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines(NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average pricing. What happened According to a f... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 1.3% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?

Viatris has had an impressive run over the past six months as its shares have beaten the S&P 500 by 34.7%. The stock now trades at $14.11, marking a 37.8% gain. This was partly due to its solid quarterly results, and the performance may ha... Full story

Yahoo Finance • 2 months ago

Theravance drops rare disease drug after late-stage trial setback

[Red arrow And dollar finance decline graph- Stock image] Baris-Ozer Theravance Biopharma (TBPH [https://seekingalpha.com/symbol/TBPH]) announced on Tuesday that it will halt its clinical program for its rare disease therapy ampreloxetine... Full story

Yahoo Finance • 2 months ago

Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value

Viatris Inc. (NASDAQ:VTRS) is one of the dirt cheap stocks to buy now. On February 26, Viatris reported a steady financial performance for the full-year 2025, generating $14.3 billion in total revenue, a 2% increase over the previous year... Full story